Statements (69)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:physicist
|
| gptkbp:associated_with |
gptkb:physicist
trauma neurotoxic effects surgical wounds injectable drugs contaminated heroin |
| gptkbp:caused_by |
gptkb:Clostridium_botulinum
|
| gptkbp:clinical_trial |
gptkb:Insurance_Company
fatigue nausea vomiting sepsis constipation dry mouth respiratory distress muscle atrophy skin lesions blurred vision dysphagia dysarthria hypotonia autonomic dysfunction ptosis urinary retention limb weakness pupillary abnormalities facial weakness flaccid paralysis bulbar weakness diminished reflexes respiratory paralysis |
| gptkbp:complications |
gptkb:cemetery
permanent nerve damage |
| gptkbp:current_use |
foodborne botulism
infant botulism |
| gptkbp:distribution |
worldwide
|
| gptkbp:duration |
weeks to months
|
| gptkbp:end_of_life |
5 to 10 percent
|
| gptkbp:first_described_by |
1951
|
| gptkbp:healthcare |
gptkb:battle
|
| https://www.w3.org/2000/01/rdf-schema#label |
wound botulism
|
| gptkbp:incubation_period |
1 to 14 days
|
| gptkbp:is_protected_by |
proper wound care
avoidance of drug use |
| gptkbp:restoration |
varies
|
| gptkbp:risk_factor |
traumatic injuries
intravenous drug use IV drug users people with chronic wounds |
| gptkbp:social_responsibility |
rare
clinical evaluation laboratory tests electromyography Clostridium botulinum type A Clostridium botulinum type B Clostridium botulinum type E Clostridium botulinum type F toxin detection |
| gptkbp:symptoms |
respiratory failure
muscle weakness difficulty swallowing slurred speech double vision |
| gptkbp:transmission |
contaminated wounds
|
| gptkbp:treatment |
supportive care
antitoxin |
| gptkbp:bfsParent |
gptkb:physicist
|
| gptkbp:bfsLayer |
2
|